From the Annual Report (you know this already):
"There are over 25 major United States hospitals nearing completion of their NovoSorb™ BTM evaluation or purchase approval process with many successful complex surgeries completed during the evaluation. We are confident that it is only a matter of time before realising our significant sales potential."
"A number of US hospitals’ burns centres have indicated their first commercial orders are imminent and we expect to be able to confirm this soon."
It now looks like $150k per sale is the average initial order - and I don't have any idea how long this stock would last before a re-order.
But if just half of the 25 hospitals place an initial order at $150k a pop that's $1.8m in sales straight off. Not enough to turn a profit but enough to build some solid sales momentum for the rest of the US.
Having been faithfully patient for so long I now think it will be worth the wait.
- Forums
- ASX - By Stock
- Ann: Further US Sales for NovoSorb BTM
From the Annual Report (you know this already): "There are over...
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.409B |
Open | High | Low | Value | Volume |
$2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 299194 | $2.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.04 | 1559 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 299194 | 2.020 |
4 | 11182 | 2.010 |
9 | 86240 | 2.000 |
1 | 1500 | 1.995 |
2 | 2005 | 1.990 |
Price($) | Vol. | No. |
---|---|---|
2.040 | 1559 | 1 |
2.050 | 5436 | 2 |
2.060 | 4936 | 1 |
2.070 | 25500 | 2 |
2.100 | 10972 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online